Tumour |
Indication |
MET status (copy
number) |
Other known mutations |
Once-daily dose that
delivers as near to tumour growth stasis as tested [mg (TG)] |
Time above pMET EC90 required to deliver tumour
stasis (hours) |
Reference |
EBC-1
|
Squamous NSCLC
|
CN gain (14)
|
P53, ATM
|
30 (76–94%)
|
12
|
(Jones et al., 2018)
This study
|
NCI-H1993
|
NSCLC
|
CN gain (14)
|
P53, STK11
|
>30 (65%)
|
14.5
|
(Henry et al., 2016)
Data on file
|
NCI-H441 |
NSCLC |
CN gain (3) |
P53, KRAS |
100 (89%) |
23 |
Data on
file |
HLXF-036LN |
NSCLC |
CN gain (3.7) |
P53 |
50 (-28%) |
18 |
(Henry et
al., 2016) |
RCC43b |
PRCC |
CN gain (8) |
BRCA1 m |
10 (100%) |
10 |
(Schuller et
al., 2015) |
RCC47 |
PRCC |
CN gain (9) |
– |
2.5 (89%) |
6 |
(Schuller et al.,
2015) |
SNU-5 |
Gastric |
CN gain (17.9) |
P53, IDH2, CDH1 |
5 (97%) |
8 |
(Cui
et al., 2011) |
Hs746T |
Gastric |
CN gain (21.3) |
P53, BRCA, APC |
2.5 (97%) |
6 |
(Gavine et al., 2015) |
MKN-45 |
Gastric |
CN gain (21) |
p53 |
25 (100%) |
11 |
This
study |
NCI-H820 |
NSCLC |
CN gain (6) |
P53, STK11 |
>30 (73%) |
12 |
Data on file |